OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lin on the Limitations of Current Biomarkers in Prostate Cancer

November 23rd 2020

Daniel W. Lin, MD, discusses the limitations of currently available biomarkers in prostate cancer.

Dr. Price on the Challenges of the CodeBreaK 100 Trial in GI Cancers

November 23rd 2020

Timothy Price, MBBS, DHthSc, FRACP, discusses challenges faced during the CodeBreaK 100 trial in gastrointestinal cancers.

Dr. Chaft on the Rationale for the OPAL Trial in EGFR+ NSCLC

November 23rd 2020

Jamie E. Chaft, MD, discusses the rationale behind the OPAL trial in EGFR-mutant non–small cell lung cancer.

Dr. Ruan on Treatment Considerations in MCL

November 23rd 2020

Jia Ruan, MD, PhD, discusses treatment considerations in mantle cell lymphoma.

Dr. Eng on Features of High-Risk CRC

November 23rd 2020

Cathy Eng, MD, FACP, FASCO, discusses the features of high-risk colorectal cancer.

Dr. Mascarenhas on Emerging Agents in Myelofibrosis

November 23rd 2020

John O. Mascarenhas, MD, discusses emerging agents in myelofibrosis.

Dr. Chaft on the Next Steps of Osimertinib Research in EGFR+ NSCLC

November 20th 2020

Jamie E. Chaft, MD, a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the next steps of osimertinib research in EGFR-mutant non–small cell lung cancer.

Dr. Tsuboi on Findings From the Phase 3 ADAURA Trial in EGFR+ NSCLC

November 20th 2020

Masahiro Tsuboi, MD, a surgeon at the National Cancer Center Hospital East in Japan, discusses findings from the phase 3 ADAURA trial in EGFR-mutant non–small cell lung cancer.

Dr. Iwata on Final OS Results From the Phase 3 IMpassion130 Trial in TNBC

November 20th 2020

Hiroji Iwata, MD, PhD, vice director and chief of Breast Oncology at Aichi Cancer Center Hospital, discusses final overall survival results from the phase 3 IMpassion130 trial in triple-negative breast cancer.

Dr. Mikhael on Unmet Needs in Triple-Class Refractory Multiple Myeloma

November 19th 2020

Joseph Mikhael, MD, discusses unmet needs in triple-class refractory multiple myeloma.

Dr. Trent on the Potential Role of Immunotherapy in GIST

November 19th 2020

Jonathan C. Trent, MD, PhD, discusses the potential role of immunotherapy in gastrointestinal stromal tumors.

Dr. Dean on Remaining Challenges in DLBCL

November 19th 2020

Robert M. Dean, MD, discusses remaining challenges in diffuse large B-cell lymphoma.

Dr. Lin on the Importance of Biomarker Research in Prostate Cancer

November 19th 2020

Daniel W. Lin, MD, discusses the importance of biomarker research in prostate cancer.

Dr. Eng on Contraindications for Oxaliplatin-Based Therapy in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses contraindications for oxaliplatin-based therapy in colorectal cancer.

Dr. Bekaii-Saab on Improved Sequencing Strategies in HCC

November 19th 2020

Tanios S. Bekaii-Saab, MD, FACP, discusses improved sequencing strategies in hepatocellular carcinoma.

Dr. Skarbnik on Current Treatment Strategies Making Waves in MCL

November 19th 2020

Alan P. Z. Skarbnik, MD, discusses treatment strategies for patients with mantle cell lymphoma.

Dr. Ayers on Recent Developments in CLL

November 19th 2020

Emily C. Ayers, MD, discusses recent developments in chronic lymphocytic leukemia.

Dr. Greene on the Future of Personalized Therapy in Prostate Cancer

November 19th 2020

Kirsten L. Greene, MD, MAS, FACS, discusses the future of personalized therapy in prostate cancer.

Dr. Janjigian on the Importance of Biomarker Testing in GI Cancers

November 19th 2020

Yelena Y. Janjigian, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the importance of biomarker testing in gastrointestinal cancers.

Dr. Eng on the Role of Preventive Screening in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of preventive screening in colorectal cancer.